Pfizer and US Government Discuss Drug Prices No Firm Commitments Yet

Pfizer CEO Albert Bourla revealed that discussions between Pfizer and the US government regarding drug price reductions have yet to result in any definitive agreements. The talks, initiated after President Donald Trump’s executive order, aim to align US drug prices with those in other high-income countries under a "Most-Favored-Nation" pricing mechanism.

The Department of Health and Human Services (HHS) expects drugmakers to lower prices to the lowest level charged globally, but experts argue the policy will be difficult to implement. Bourla, speaking at the Goldman Sachs Global Healthcare Conference, described the meetings as cordial but lacking substance, focusing on broad concepts rather than specific details.

Bourla also suggested Pfizer may adjust its approach in countries where price controls are mandated. He hinted that Pfizer might withdraw reimbursement options in regions that fail to increase prices, although the company would keep products available in open markets.

Meanwhile, HHS indicated its intent to create a system allowing Americans to buy medicines directly at the lowest international price. This bold move is part of the government’s strategy to negotiate fair and transparent pricing for US consumers.

The pharmaceutical industry, represented by lobby group PhRMA, has maintained limited transparency in its discussions with the administration. As global drug pricing pressure mounts, the outcome of these negotiations could reshape the pharmaceutical landscape.